TAVR Offers Better Quality of Life to Low Risk Patients

Courtesy of Dr. Carlos Fava.

As we all know, TAVR is gaining ground fast in the lower risk patient population, but in addition to analyzing the most important events, researchers are increasingly looking at health status, not only at hospital level, but also after one year.  

TAVI en insuficiencia aórtica pura

This study looked into PARTNER 3 patient health status at 1, 6 and 12 months after procedure with the Kansas City Cardiomyopathy Questionnaire (KCCQ), SF-36 and EQ-5D.

Primary end point (PFP) were changes in KCCQ-Overall Summary (KCCQ-OS) over time.

At 30 days, TAVR was associated to better health status (a 16-point difference in KCCQ-OS vs. SAVR (p<0.001).

Read also: Major Bleeding in Patients with Aspirin Plus Rivaroxaban.

At 6 and 12 months, TAVR also presented better health status, but the effect saw a reduction over time (KCCQ-OS 2.6 and 1.8 points respectively; p<0.04 for both). In addition, TAVR showed more patients with excellent evolution (alive and with KCCQ-OS ≥ 75) at 6 months (90.3% vs. 85.3%; p=0.03) and at 12 months (87.3% vs. 82.8%; p=0.07). 


Low-risk patients with severe aortic stenosis undergoing TAVR were associated with significantly better early and late health compared against SAVR. 

Courtesy of Dr. Carlos Fava.

Original Title: Health Status after Transcatheter vs. Surgical Aortic Valve Replacement in Low-Risk Patients with Aortic Stenosis.

Reference: Suzanne J. Baron, et al. J Am Coll Cardiol Article in press.

Would you like to receive a weekly summary of the most recent scientific articles?

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.